PRESS RELEASES

Date Title View
Toggle Summary Chimerix Appoints Vicki Vakiener to Board of Directors
DURHAM, N.C. , April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Vicki Vakiener to its Board of Directors, effective
View HTML
Toggle Summary Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
DURHAM, N.C. , April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research
View HTML
Toggle Summary Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
DURHAM, N.C. , March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will participate in a pre-recorded
View HTML
Toggle Summary Chimerix Reports Fourth Quarter and Year End 2020 Financial Results and Provides Operational Update
– Acquisition of Oncoceutics Adds Late-Stage Precision Oncology Pipeline – – Recently Completed Financing Supports Broad Investment Across Pipeline – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company
View HTML
Toggle Summary Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT
– Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, reported topline results today from the first cohort of
View HTML
Toggle Summary Chimerix to Report Fourth Quarter and Year End 2020 Financial Results and Provide an Operational Update on February 25, 2021
DURHAM, N.C. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, February 25,
View HTML
Toggle Summary Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
DURHAM, N.C. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix , Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the closing of its previously announced underwritten public offering of
View HTML
Toggle Summary Chimerix Announces Pricing of Public Offering of Common Stock
DURHAM, N.C. , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix , Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the pricing of its underwritten public offering of 11,765,000 shares of its
View HTML
Toggle Summary Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock
DURHAM, N.C. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix , Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today that it intends to offer and sell, subject to market and other conditions, up
View HTML
Toggle Summary Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million Management to Host
View HTML